| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
5-HT(7) receptor (competitive binding), alpha-Glucosidase (IC50: 19.24 +/- 1.73 uM)
|
|---|---|
| ln Vitro |
In yeast alpha-glucosidase assay, p-Hydroxyphenethyl trans-ferulate demonstrates anti-hyperglycemic activity with an IC50 of 19.24 +/- 1.73 uM. It also exhibits potent antioxidant and anti-inflammatory activities. In Hepa 1c1c7 cells, it doubles quinone reductase specific activity at 2.1 ug/mL (6.6 uM). The compound shows affinity toward 5-HT(7) receptors in a competitive binding assay and exhibits anticancer activity.
|
| ln Vivo |
No specific in vivo data available for this pure compound alone. Related phenolic compounds from similar plant sources (Sida acuta, Sida rhombifolia) have demonstrated anti-hyperglycemic effects in animal models. The compound is expected to be absorbed following oral administration and may exhibit systemic effects including blood glucose reduction and anti-inflammatory activity based on its in vitro profile.
|
| Enzyme Assay |
Recombinant human 5-HT(7) receptor membrane preparations are incubated with [3H]-LSD as a radioligand and varying concentrations of the test compound (0.1 nM-100 uM) in binding buffer (Tris-HCl, pH 7.4, MgCl2, EDTA) at 27degC for 60 minutes. Nonspecific binding is determined using serotonin (10 uM). Bound radioactivity is separated by rapid filtration through GF/B filters and quantified by liquid scintillation counting. Competitive binding curves are generated and Ki values are calculated. For alpha-glucosidase assay: yeast alpha-glucosidase is incubated with 4-nitrophenyl-alpha-D-glucopyranoside (pNPG) substrate and test compound at 37degC for 20 minutes; absorbance is measured at 405 nm.
|
| Cell Assay |
Hepa 1c1c7 mouse hepatoma cells are cultured in alpha-MEM medium supplemented with 10% FBS and antibiotics. Cells are seeded in 96-well plates and treated with p-Hydroxyphenethyl trans-ferulate (0.1-100 uM) for 24-48 hours. Quinone reductase (QR) activity is measured by cell lysis followed by addition of a reaction mixture containing menadione, glucose-6-phosphate, glucose-6-phosphate dehydrogenase, NADP+, MTT, and BSA. Absorbance is read at 610 nm. Specific QR activity is calculated as nmol/min/mg protein. The compound (2.1 ug/mL, 6.6 uM) doubles QR specific activity, indicating phase II enzyme induction.
|
| Animal Protocol |
No published in vivo animal study for this compound alone. Based on similar natural product studies, a typical protocol for evaluating anti-hyperglycemic activity would involve oral administration to streptozotocin-induced diabetic rats (20-100 mg/kg) once daily for 14-28 days. Endpoints include fasting blood glucose, serum insulin, oral glucose tolerance test (OGTT), HbA1c, serum lipid profile, and inflammatory markers (TNF-alpha, IL-6). For antioxidant assessment, liver and kidney tissues would be collected for measurement of SOD, CAT, GSH-Px, and MDA levels.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data for this compound. Based on its molecular properties (MW 314.33, LogP estimation ~2-3), it is likely to be absorbed after oral administration and distributed to tissues. Metabolism would likely occur via phase II conjugation (glucuronidation, sulfation) and possibly phase I demethylation. Plasma half-life, Cmax, AUC, and bioavailability have not been determined experimentally. Solubility in DMSO is 55-100 mg/mL, facilitating in vivo formulation.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for p-Hydroxyphenethyl trans-ferulate. Related hydroxycinnamic acid derivatives (e.g., ferulic acid, caffeic acid) exhibit low toxicity with oral LD50 > 2000 mg/kg in rodents and are generally recognized as safe at dietary levels. No genotoxicity or significant organ toxicity has been reported for this class of compounds. For research use, standard laboratory safety precautions (gloves, lab coat, eye protection) should be followed.
|
| References |
|
| Additional Infomation |
p-Hydroxyphenylethyl trans-ferulate is a hydroxycinnamic acid. It has been reported in Angelica sinensis, Celandine oleracea, and other organisms with available data.
p-Hydroxyphenethyl trans-ferulate (CAS: 84873-15-4) is a natural product isolated from green onion (Allium spp.), Sida acuta, Sida rhombifolia, and Angelica gigas. It has been investigated for anti-hyperglycemic (alpha-glucosidase inhibition), antioxidant, anti-inflammatory, anticancer, and serotonergic (5-HT(7) receptor binding) activities. The compound is supplied as a white to off-white solid. Molecular formula: C18H18O5, molecular weight: 314.33. Soluble in DMSO (55-100 mg/mL). For research use only. Not approved for clinical use. Reference: Xiao H, Parkin K. J Agric Food Chem. 2006;54(22):8417-24; Arciniegas A, et al. Quim Nova. 2017;40(2). |
| Molecular Formula |
C18H18O5
|
|---|---|
| Molecular Weight |
314.33
|
| Exact Mass |
314.115
|
| CAS # |
84873-15-4
|
| PubChem CID |
637308
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
530.1±50.0 °C at 760 mmHg
|
| Melting Point |
165 - 166 °C
|
| Flash Point |
193.3±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.627
|
| LogP |
2.86
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)/C=C/C(=O)OCCC2=CC=C(C=C2)O)O
|
| InChi Key |
JMSFLLZUCIXALN-WEVVVXLNSA-N
|
| InChi Code |
InChI=1S/C18H18O5/c1-22-17-12-14(4-8-16(17)20)5-9-18(21)23-11-10-13-2-6-15(19)7-3-13/h2-9,12,19-20H,10-11H2,1H3/b9-5+
|
| Chemical Name |
2-(4-hydroxyphenyl)ethyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (318.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1814 mL | 15.9068 mL | 31.8137 mL | |
| 5 mM | 0.6363 mL | 3.1814 mL | 6.3627 mL | |
| 10 mM | 0.3181 mL | 1.5907 mL | 3.1814 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
